Literature DB >> 2684523

Effects of recombinant human erythropoietin treatment in end-stage renal failure patients. Results of a multicenter phase II/III study.

M Pollok1, J Bommer, H J Gurland, K M Koch, W Schoeppe, P Scigalla, C A Baldamus.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2684523     DOI： 10.1159/000417896

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN： 0302-5144            Impact factor:   1.580


× No keyword cloud information.
  4 in total

Review 1.  Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?

Authors:  Farhanah Yousaf; Bruce Spinowitz
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

2.  Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease.

Authors:  M E Stevens; G P Summerfield; A A Hall; C A Beck; A J Harding; J R Cove-Smith; A D Paterson
Journal:  BMJ       Date:  1992-02-22

3.  Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR.

Authors:  Jula K Inrig; Shelly Sapp; Huiman Barnhart; Uptal D Patel; Donal Reddan; Ajay Singh; Robert M Califf; Lynda Szczech
Journal:  Nephrol Dial Transplant       Date:  2012-05-09       Impact factor: 5.992

4.  Effect of erythropoiesis-stimulating agents on blood pressure in pre-dialysis patients.

Authors:  Marit M Suttorp; Tiny Hoekstra; Moshe Mittelman; Ilka Ott; Casper F M Franssen; Friedo W Dekker
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.